On July 5, 2021, Zylox-Tonbridge Medical Technology (“Zylox-Tonbridge”, stock code: 2190.HK), the market leader in neurological and peripheral vascular interventional medical devices in China, successfully listed on the Main Board of HKEx with the issue price at HKD 42.7 and was oversubscribed by more than 1,190 times, raising over HKD 2.56 billion (before the exercise of the over-allotment option). Grandall Shanghai Office has been retained as the issuer's Chinese legal advisor with ZHANG Xiaolong, CHEN Qianwen and SHI Jingjing as key lawyers serving the project.  

Since its establishment in 2012, Zylox-Tonbridge, the market leader in neurological and peripheral vascular interventional medical devices in China, has established a full line of solutions in neurological and peripheral vascular interventions, and developed a portfolio of 45 products and product candidates. Its current therapeutic areas include acute ischemic stroke, intracranial aneurysm and carotid stenosis, peripheral arterial and venous disease, and dialysis-related diseases.